1

An Unbiased View of LDN-27219 as a cancer drug candidate

News Discuss 
1 significantly exciting compound is LDN-27219. While most tTG inhibitors are built to bind towards the protein crosslinking Energetic web-site, LDN-27219 as an alternative binds into the nucleotide binding pocket from the enzyme when it is actually in its shut-state conformation, and stabilizes that conformation to stop crosslinking activity.78 Schneider https://zandergdfez.blazingblog.com/31643640/about-ldn-27219-drug-development-pipeline

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story